CCG
NVO

Cloverfields Capital Group’s Novo Nordisk NVO Stock Holding History

Cloverfields Capital Group’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-36,354
Closed -$2.02M – 96
2025
Q3 		$2.02M Sell
36,354
-3,368
-8% -$197K 0.63% 58
2025
Q2 		$2.74M Buy
39,722
+13,533
+52% +$921K 0.81% 53
2025
Q1 		$1.82M Buy
26,189
+313
+1% +$25.9K 0.6% 61
2024
Q4 		$2.23M Buy
25,876
+2,900
+13% +$314K 0.72% 49
2024
Q3 		$2.74M Sell
22,976
-3,773
-14% -$503K 0.88% 45
2024
Q2 		$3.82M Buy
26,749
+239
+0.9% +$31.7K 1.29% 34
2024
Q1 		$3.4M Buy
26,510
+283
+1% +$33.7K 1.15% 36
2023
Q4 		$2.71M Sell
26,227
-2,099
-7% -$208K 1.06% 40
2023
Q3 		$2.58M Hold
28,326
– – 1.16% 33
2023
Q2 		$2.29M Buy
28,326
+10,048
+55% +$821K 0.74% 39
2023
Q1 		$1.45M Buy
18,278
+7,898
+76% +$560K 0.43% 44
2022
Q4 		$702K Sell
10,380
-6,344
-38% -$372K 0.22% 45
2022
Q3 		$833K Buy
16,724
+140
+0.8% +$7.5K 0.28% 43
2022
Q2 		$924K Sell
16,584
-290
-2% -$16.1K 0.28% 44
2022
Q1 		$937K Sell
16,874
-4,122
-20% -$212K 0.29% 41
2021
Q4 		$1.18M Hold
20,996
– – 0.37% 42
2021
Q3 		$1.01M Buy
20,996
+146
+0.7% +$7.06K 0.32% 41
2021
Q2 		$873K Buy
20,850
+254
+1% +$9.85K 0.25% 44
2021
Q1 		$694K Buy
20,596
+304
+1% +$10.8K 0.22% 47
2020
Q4 		$709K Buy
+20,292
New +$701K 0.27% 43

Other funds holding NVO

Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Cloverfields Capital Group's NVO Position: Q4 2025 in Review

Cloverfields Capital Group sold out of Novo Nordisk (NVO) in Q4 2025, closing a stake of 36,354 shares — an estimated $2.02M sold.

Cloverfields Capital Group first reported a position in NVO in Q4 2020 and held it in 20 quarters. The position peaked at $3.82M in Q2 2024. 1,418 funds tracked by Wall St. Rank hold NVO as of Q4 2025.

  • Cloverfields Capital Group reported no remaining Novo Nordisk position as of Q4 2025 after selling out during the quarter.
  • Cloverfields Capital Group sold 36,354 Novo Nordisk shares in Q4 2025, an estimated $2.02M.
  • Cloverfields Capital Group first reported a position in Novo Nordisk in Q4 2020 and held it in 20 quarters.
  • Cloverfields Capital Group's Novo Nordisk position peaked at $3.82M in Q2 2024.
  • 1,418 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2025.

Based on Cloverfields Capital Group's 13F filing for Q4 2025, filed 13 Feb 2026.